Skip to main content
TipRanks
Go Ultimate75% OFF

XORTX Therapeutics Inc (XRTX) AI Stock Analysis

83 Followers
XRTX

XORTX Therapeutics Inc

(NASDAQ:XRTX)

Select Model
Rating:39Underperform
Price Target:$1.00â–¼(-9.09% Downside)
Action:reiterated
Date:11/15/26

The score is dominated by weak fundamentals: XORTX generates no revenue, loses money consistently, and burns roughly $4.9M of operating cash annually against an asset base of only ~$5.8M, creating meaningful financing and dilution risk despite a clean, debt-free balance sheet and a notable reduction in losses since 2022. Technicals reinforce caution, with the shares trading far below their 50-, 100-, and 200-day moving averages and MACD still negative, though a move back above the 20-day average and neutral RSI hint at near-term stabilization. Valuation offers no support, with a negative P/E and no dividend, leaving the investment case dependent on clinical milestones rather than financial performance.

Positive Factors
Patent Portfolio ExpansionThe Japanese patent allowance expands protection for XORTX’s xanthine oxidase inhibitor platform in an important market and strengthens the defensibility of XRx-101. Broader patent coverage can support future regulatory, partnering, and commercialization efforts if clinical development succeeds.
Negative Factors
Pre-Revenue Loss ProfileThe absence of revenue means XORTX has not yet demonstrated commercial demand or a self-funding business model. Persistent losses leave future performance dependent on successful clinical development and eventual product sales, making profitability highly contingent on pipeline execution.

XORTX Therapeutics Inc (XRTX) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%XRTX-60.07%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.00M
Dividend Yield
―
Average Volume (3M)
758.37K
Price to Earnings (P/E)
-0.5
Beta (1Y)
0.69
Revenue Growth
―
EPS Growth
2.68%
Country
US
Employees
2
Sector
General
Sector Strength
55
Industry
Biotechnology

XORTX Therapeutics Inc Business Overview & Revenue Model

Company Description

XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephro...

XORTX Therapeutics Inc Financial Statement Overview

Summary

XORTX is a pre-revenue, clinical-stage biotech with zero sales in every reported period and uninterrupted losses (TTM net loss ~$3.5M, operating loss ~$3.6M). Cash generation is negative across all periods, with TTM operating outflow of roughly $4.9M against a total asset base of only ~$5.8M, implying a short runway and dependence on further equity financing. The balance sheet is the one bright spot: essentially debt-free with ~$5.1M of equity, and losses and burn have narrowed substantially from the 2022 peak. However, equity has eroded from $13.2M in 2021 and recent recovery appears driven by share issuance, leaving ongoing dilution risk and deeply negative returns on shareholder capital.

Income Statement

13Very Negative

Balance Sheet

36Negative

Cash Flow

19Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue000000
Gross Profit-143.25K0-111.64K00-18.02K
EBITDA-3.41M-3.14M-3.80M-5.91M-12.44M-2.90M
Net Income-3.48M-2.66M-3.15M-2.16M-10.45M―
Balance Sheet
Total Assets5.81M2.68M4.09M5.47M12.37M17.38M
Cash, Cash Equivalents and Short-Term Investments318.85K862.94K2.47M3.45M10.43M14.87M
Total Debt037.22K38.78K11.51K77.60K0
Total Liabilities680.82K597.98K757.99K825.94K5.38M4.18M
Stockholders Equity5.12M2.08M3.34M4.64M7.00M13.20M
Cash Flow
Free Cash Flow-1.23M-2.82M-3.72M-6.63M-9.01M-4.83M
Operating Cash Flow-4.92M-2.82M-3.68M-6.58M-8.96M-4.80M
Investing Cash Flow-440.53K-300.12K-38.92K-46.36K-45.70K-31.81K
Financing Cash Flow4.47M1.45M2.78M-361.04K3.91M19.37M

XORTX Therapeutics Inc Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.10

Price Trends

50DMA1.47Negative
100DMA1.79Negative
200DMA2.04Negative

Market Momentum

MACD-0.15Negative
RSI47.84Neutral
STOCH44.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRTX, the sentiment is Neutral. The current price of 1.10 is above the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.47, and below the 200-day MA of 2.04, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 47.84 is Neutral, neither overbought nor oversold. The STOCH value of 44.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XRTX.

XORTX Therapeutics Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

XRTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
XRTXXRTX39Underperform$2.00M-0.48-99.49%――2.68%

* General Sector Average

Performance Comparison

-60%-40%-20%0%20%XRTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
XRTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
XRTXXortx Therapeutics1.10-1.58-58.96%

XORTX Therapeutics Inc Corporate Events

XORTX Therapeutics Reports Japan Patent Allowance for XRx-101

Nov 13, 2026

In a Nov. 13, 2026 announcement, XORTX Therapeutics said the Japan Patent Office had issued a Decision to Grant for an application covering pharmaceutical compositions with xanthine oxidase inhibitors, including oxypurinol, for treating or preventing...

XORTX Moves to File Health Canada Trial Application for XRx-026 Gout Program

Oct 8, 2026

On October 8, 2026, XORTX Therapeutics outlined its planned Clinical Trial Application to Health Canada for XRx-026, a gout program built around XORLO, its proprietary oxypurinol formulation, as part of a two-part XRX-OXY-102 clinical study. The comp...

XORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Therapy

Sep 18, 2026

On September 18, 2026, XORTX Therapeutics outlined plans to submit an Investigational New Drug application to the U.S. FDA in the fourth quarter of 2026 for its XRx-026 gout program, built around its proprietary XORLO formulation of oxypurinol. The c...

XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program

Sep 10, 2026

On September 10, 2026, XORTX Therapeutics announced it has initiated contract manufacturing of GMP oxypurinol drug substance and commercial-scale XORLO tablets to supply its planned XRX-OXY-102 clinical trial in gout and to generate data needed for e...

XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign

Sep 4, 2026

On August 28, 2026, XORTX Therapeutics received final approval to voluntarily delist its common shares from the TSX Venture Exchange, with the delisting taking effect after the close of business on September 1, 2026. The company’s shares continue to...

XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting

Aug 28, 2026

On Aug. 28, 2026, XORTX Therapeutics Inc. reported that it had terminated and rescinded an investor relations and marketing agreement with IR Agency LLC, effective Aug. 7, 2026, and that all US$2.5 million in prepaid fees were returned to the company...

XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet

Aug 17, 2026

On August 14, 2026, XORTX Therapeutics Inc. filed a Form 6-K for the month of August 2026, providing unaudited condensed interim consolidated financial statements and related disclosures for the three and six months ended June 30, 2026. The filing, s...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 15, 2026